Lite Strategy Inc. Common Stock (LITS)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, Lite Strategy was priced at $1.21 with a $36.8M market cap. I see a clinical-stage cancer company that also holds Litecoin as a reserve asset, run by only five employees, with no meaningful revenue in the last two filed fiscal years. In fiscal 2024, the year ended 2024-06-30, it earned $18.0M on $65.3M of revenue. But fiscal 2025, the year ended 2025-06-30, swung to a $15.9M net loss, and fiscal 2026, the year ended 2026-06-30, produced a $71.2M net loss. The quarterly losses have been heavy: in fiscal Q2 2026, the quarter ended 2025-12-31, net loss was $30.8M; in fiscal Q3 2026, the quarter ended 2026-03-31, net loss was $23.7M. The balance-sheet optics are not alarming on one FairStock measure: P/B is 0.95 and Altman Z-Score is 12.20, but Piotroski is only 2/9, ROE is -243.02%, ROCE is -24.74%, and trailing free cash flow is -$10.4M, a -28.3% FCF yield. FairStock's profit growth figure of -820.87% underscores the swing. That tells me asset value may be real, but the cash engine is broken. A moat in biotech is a pipeline with patent protection and proven commercial execution; here I cannot identify one from the figures. The FairStock Lynch category is TURNAROUND—loss in the latest year after earlier profits—which fits, but turnarounds need improving operations, not just a low price. I would need evidence that losses are shrinking and revenue or cash flow is returning before calling this a margin-of-safety bargain. The low beta of 0.01 does not compensate for business risk.

In plain English: Lite Strategy is a small healthcare company that develops cancer therapies and also holds Litecoin as a reserve asset. The business looks weak right now: it had no reported revenue in the last two fiscal years and lost $71.2 million in fiscal 2026 after earning a profit in fiscal 2024. At $1.21, the stock price is close to the company's accounting net asset value, but because it is losing money and spending cash, it looks more like a speculative turnaround than a clear bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer